Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-011 for Moderate to Severe Knee Osteoarthritis Pain
NCT07308834Phase 2Recruiting
- Sponsor
- CarthroniX
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of CX-011 in osteoarthritis (OA) (4 arms), sponsored by CarthroniX. Primary endpoints: Treatment-Emergent Adverse Events at 24 weeks and Change from baseline in clinical laboratory parameters at 24 weeks. Started Aug 2026; status: recruiting.
02
Drugs
CX-011
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07308834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308834.